Cipla Limited – FDA 483, Jun 21, 2024
Cipla Limited, a drug manufacturer in Verna, India, received a Form 483 with six observations during an FDA inspection from June 10-21, 2024. The observations highlight significant deficiencies in test method validation, environmental monitoring for aseptic processing, cleaning and disinfection procedures, and investigation of batch failures. Additionally, issues were noted with computer system access controls and adherence to quality control unit procedures.
ID · 8db1e1bc-0bc5-4334-9558-e7aa003c3b7d
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.